|Journal||Blood Cancer Journal|
|Publication status||Published - 12 Jan 2023|
The authors would like to thank the Multiple Myeloma Research Foundation (MMRF) for making the CoMMpass registry data available. This research was supported by the NIH/NCI Cancer Center Support Grant P30 CA008748 (U.A.S., A.M.L., S.M., and S.Z.U.), the Allen Foundation Inc (U.A.S.), the International Myeloma Society (U.A.S.), the NCI MSK Paul Calabresi Career Development Award for Clinical Oncology 2K12CA184746 (U.A.S), the Paula and Rodger Riney Foundation (U.A.S., A.M.L., and O.L.), the American Society of Hematology Clinical Research Training Institute Award (U.A.S.) and the TREC Training Workshop R25CA203650 (PI: Melinda Irwin) (U.A.S. and C.R.M.). This study was funded in part by the National Institutes of Health under award numbers F32 CA220859 and K22 CA251648 (C.R.M.) and the American Cancer Society PF-17-231-01-CCE (C.R.M.). This research was also supported by a Stand Up To Cancer Dream Team Research Grant SU2C-AACR-DT28-18 (PI: Irene Ghobrial)(C.R.M.). Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of Stand Up To Cancer. Opinions, interpretations, conclusions, and recommendations are those of the author(s) and are not necessarily endorsed by Stand Up To Cancer, the Entertainment Industry Foundation, or the American Association for Cancer Research.